Table 3 Results of meta-analyses
| Â | Â | Â | Psychotherapy+Benzodiazepine vs Psychotherapy alone | Psychotherapy+Benzodiazepine vs Benzodiazepine alone | ||||
|---|---|---|---|---|---|---|---|---|
| Â | Â | Statistical method | Number of comparisons | Number of participants | Effect size [95% CI] | Number of comparisons | Number of participants | Effect size [95% CI] |
Acute phase treatment (at 2–4 months) | Response | RR | 2 | 166 | 1.25 [0.78, 2.03] | 1 | 77 | 1.57 [0.83, 2.98] |
| Â | Global severity | SMD | 2 | 122 | 0.15 [-0.21, 0.50] | 1 | 68 | 0.63 [0.14, 1.11] |
| Â | Frequency of panic attacks | SMD | 2 | 124 | 0.38 [0.02,0.74] | 1 | 68 | 0.18 [-0.29, 0.66] |
| Â | Phobic avoidance | SMD | 2 | 122 | 0.09 [-0.27, 0.45] | 1 | 68 | 1.17 [0.65, 1.68] |
| Â | General anxiety | SMD | 1 | 60 | 0.08 [-0.43, 0.59] | 0 | 0 | Not estimable |
| Â | Depression | SMD | 2 | 120 | 0.17 [-0.23, 0.58] | 1 | 68 | 0.14 [-0.34, 0.62] |
| Â | Social functioning | SMD | 1 | 64 | 0.51 [0.01, 1.01] | 1 | 68 | 1.05 [0.54, 1.56] |
|  | Dropouts for any reason within 2–4 months | RR | 2 | 166 | 0.81 [0.47, 1.38] | 1 | 77 | 1.85 [0.50, 6.87] |
|  | Dropouts due to side effects within 2–4 months | RR | 0 | 0 | Not estimable | 0 | 0 | Not estimable |
Immediately after the end of drug taper | Response | RR | 2 | 166 | 0.78 [0.45, 1.35] | 1 | 77 | 3.39 [1.03, 11.21] |
| Â | Global/Avoidance/Panic | SMD | 2 | 99 | -0.31 [-0.71, 0.09] | 1 | 53 | 0.75 [0.19, 1.31] |
6–12 months after treatment termination | Response | RR | 2 | 166 | 0.62 [0.36, 1.07] | 1 | 77 | 2.31 [0.79, 6.74] |
| Â | Global/Avoidance/Panic | SMD | 2 | 95 | -0.19 [-0.59, 0.22] | 1 | 35 | 0.99 [0.28, 1.70] |